1e
19
1
49
2
2
18
1b
1d
18
33
63
1d
2 29
1d
25
Steven Joffe, MD, MPH
88
63
Art and Ilene Penn Professor of Medical Ethics & Health Policy
28
55
3
77
Member, Abramson Cancer Center
7c
Member, Institute for Translational Medicine and Therapeutics (ITMAT)
5d
Senior Fellow, Leonard Davis Institute
e8
Director, Postdoctoral T32 Training Program in the Ethical, Legal and Social Implications (ELSI) of Genetics and Genomics, University of Pennsylvania Perelman School of Medicine
68
Senior Fellow, Penn Center for Precision Medicine
ae
Interim Chair (2019-22) and Chair (2022- ), Department of Medical Ethics and Health Policy, Perelman School of Medicine
11
Department: Medical Ethics and Health Policy
4
1
b
1d
46
Contact information
6c
4
3
3
1d
6c
3600 Civic Center Blvd 8W 101A
Philadelphia, PA 19104-4865
26
Philadelphia, PA 19104-4865
2e
Office: 215-898-3055
32 Fax: 215-573-3036
24
81
32 Fax: 215-573-3036
24
Email:
joffes@upenn.edu
12
joffes@upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
b7 Search PubMed for articles
d
4
b
1f
b7 Search PubMed for articles
d
13
Education:
21 9 A.B. 15 (Fine Art) c
28 Harvard College, 1988.
21 9 M.D. 15 (Medicine) c
53 University of California, San Francisco School of Medicine, 1992.
21 b M.P.H. 19 (Epidemiology) c
3b University of California, Berkeley, 1996.
c
3
3
3
3
8d
Permanent link21 9 A.B. 15 (Fine Art) c
28 Harvard College, 1988.
21 9 M.D. 15 (Medicine) c
53 University of California, San Francisco School of Medicine, 1992.
21 b M.P.H. 19 (Epidemiology) c
3b University of California, Berkeley, 1996.
c
2 29
21
1e
1d
24
2b
29
27
23
1a0 Lynch HF, Ramachandran R, Sachs R, Joffe S, Zettler PJ: The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1). Health Affairs Forum January 2026 Notes: Available at https://www.healthaffairs.org/content/forefront/promise-and-perils-fda-s-new-plausible-mechanism-pathway-part-1. DOI 10.1377/forefront.20260120.557793.
1a0 Lynch HF, Ramachandran R, Sachs R, Joffe S, Zettler PJ: The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2). Health Affairs Forum January 2026 Notes: Available at https://www.healthaffairs.org/content/forefront/promise-and-perils-fda-s-new-plausible-mechanism-pathway-part-2. DOI 10.1377/forefront.20260121.824818.
c9 Joffe S: The ethics of heritable human genome editing. Fertil Steril 124, Nov 2025 Notes: doi: 10.1016/j.fertnstert.2025.05.141.
206 Sarah Scollon S, Plon SE, Joffe S, Biegel JA, Kulkarni S, Miles G, Patton DR, Coffey B, Winter CL, Tsongalis GJ, Routbort MJ, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg, SL, Fox E, Weigel B, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW: Germline Cancer Predisposition Results from the NCI-COG Pediatric MATCH Trial. J Precision Oncol 9, Oct 2025 Notes: doi: 10.1200/PO-25-00742. Epub 2025 Oct 30.
148 Parikh RB, Ulloa-Perez E, Kurian M, Hubbard R, Joffe S, Fernandez Lynch H, Mamtani R: Prescribing changes after accelerated vs regular approval of oncology therapies. JAMA Netw Open 8(7): e2520726, July 2025 Notes: doi: 10.1001/jamanetworkopen.2025.20726.
128 McCoy MS, Gaines ME, Joffe S, Kanter GP, Largent EA, Lo B, Lynch HF, Whelan AM, Mello MM.: A Framework for Assessing the Permissibility of Academic Leaders' Outside Activities Milbank Q Jun 2025 Notes: Epub ahead of print.
1fd Callahan KP, Mueller R, Joffe S, Skraban C, Spinner NB, Crew K, Clapp J, Munson D, Feudtner C.: Parents' perceptions of the utility of genetic testing in the NICU. Genet Med 27(6): 101393, June 2025 Notes: doi: 10.1016/j.gim.2025.101393. Epub ahead of print Feb 2025. Response to letter to the editor: Callahan KP, Mueller R, Joffe S, Skraban C, Spinner N, Crew K, Clapp J, Munson D, Feudtner C. Genetics in Medicine 28(1):101639, 2026.
5b Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, 143 Joffe S, Mamtani R, Parikh RB, Fernandez Lynch H: Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis. BMJ Oncology 4(1), May 2025.
fd Zettler PJ, Sachs RE, Joffe S, Lynch HF: The Dangers of Decoupling Safety and Effectiveness in Drug Approval. JAMA Mar 2025 Notes: doi: 10.1001/jama.2025.2807. Epub ahead of print.
2c
7
1d
1f
Selected Publications
14d Joffe S, Bair EF, Gleason KA, Sellers DE, McGraw SA, Gross CP, Chen DT, Campbell EG, Mello MM: Stakeholder views about the responsibilities of principal investigators in multicenter randomized controlled trials Clin Trials Feb 2026 Notes: Epub ahead of print.1a0 Lynch HF, Ramachandran R, Sachs R, Joffe S, Zettler PJ: The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1). Health Affairs Forum January 2026 Notes: Available at https://www.healthaffairs.org/content/forefront/promise-and-perils-fda-s-new-plausible-mechanism-pathway-part-1. DOI 10.1377/forefront.20260120.557793.
1a0 Lynch HF, Ramachandran R, Sachs R, Joffe S, Zettler PJ: The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2). Health Affairs Forum January 2026 Notes: Available at https://www.healthaffairs.org/content/forefront/promise-and-perils-fda-s-new-plausible-mechanism-pathway-part-2. DOI 10.1377/forefront.20260121.824818.
c9 Joffe S: The ethics of heritable human genome editing. Fertil Steril 124, Nov 2025 Notes: doi: 10.1016/j.fertnstert.2025.05.141.
206 Sarah Scollon S, Plon SE, Joffe S, Biegel JA, Kulkarni S, Miles G, Patton DR, Coffey B, Winter CL, Tsongalis GJ, Routbort MJ, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg, SL, Fox E, Weigel B, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW: Germline Cancer Predisposition Results from the NCI-COG Pediatric MATCH Trial. J Precision Oncol 9, Oct 2025 Notes: doi: 10.1200/PO-25-00742. Epub 2025 Oct 30.
148 Parikh RB, Ulloa-Perez E, Kurian M, Hubbard R, Joffe S, Fernandez Lynch H, Mamtani R: Prescribing changes after accelerated vs regular approval of oncology therapies. JAMA Netw Open 8(7): e2520726, July 2025 Notes: doi: 10.1001/jamanetworkopen.2025.20726.
128 McCoy MS, Gaines ME, Joffe S, Kanter GP, Largent EA, Lo B, Lynch HF, Whelan AM, Mello MM.: A Framework for Assessing the Permissibility of Academic Leaders' Outside Activities Milbank Q Jun 2025 Notes: Epub ahead of print.
1fd Callahan KP, Mueller R, Joffe S, Skraban C, Spinner NB, Crew K, Clapp J, Munson D, Feudtner C.: Parents' perceptions of the utility of genetic testing in the NICU. Genet Med 27(6): 101393, June 2025 Notes: doi: 10.1016/j.gim.2025.101393. Epub ahead of print Feb 2025. Response to letter to the editor: Callahan KP, Mueller R, Joffe S, Skraban C, Spinner N, Crew K, Clapp J, Munson D, Feudtner C. Genetics in Medicine 28(1):101639, 2026.
5b Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, 143 Joffe S, Mamtani R, Parikh RB, Fernandez Lynch H: Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis. BMJ Oncology 4(1), May 2025.
fd Zettler PJ, Sachs RE, Joffe S, Lynch HF: The Dangers of Decoupling Safety and Effectiveness in Drug Approval. JAMA Mar 2025 Notes: doi: 10.1001/jama.2025.2807. Epub ahead of print.
2c